Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HRGN's EV-to-EBITDA is ranked worse than 100% of 1659
companies
in the Consumer Packaged Goods industry
Industry Median: 9.25
vs HRGN: -5.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Harvard Apparatus Regenerative Technology's PE Ratio (TTM) for today is calculated as:
Harvard Apparatus Regenerative Technology's share price for today is $1.96.
Harvard Apparatus Regenerative Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HRGN vs STCB, BRLS, DTEAF: EV-to-EBITDA Comparison
For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Apparatus Regenerative Technology EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Harvard Apparatus Regenerative Technology's EV-to-EBITDA falls into.
Harvard Apparatus Regenerative Technology's current Enterprise Value is $34.75 Mil.
Harvard Apparatus Regenerative Technology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology (HRGN) has a EV-to-EBITDA of -5.30 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Harvard Apparatus Regenerative Technology. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #999999 out of 1659 companies in the Consumer Packaged Goods industry.
Is Harvard Apparatus Regenerative Technology's EV-to-EBITDA too high?
Harvard Apparatus Regenerative Technology's current EV-to-EBITDA is -5.30. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #999999 out of 1659 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's EV-to-EBITDA compare to STCB and BRLS?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #999999 out of 1659 companies for EV-to-EBITDA. This places Harvard Apparatus Regenerative Technology in the lower half of its industry. The industry median EV-to-EBITDA is 9.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.25, based on 1,659 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Harvard Apparatus Regenerative Technology. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current EV-to-EBITDA is -5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Harvard Apparatus Regenerative Technology (HRGN) has a current EV-to-EBITDA of -5.30. The current EV-to-EBITDA is -5.30. Harvard Apparatus Regenerative Technology's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current EV-to-EBITDA is -5.30 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
13GF Score
Get the complete analysis for HRGN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRGN has been successfully added to your 
